Vice President Project

Jack H. Suggs

e: abne60@r.postjobfree.com ( t: 917-***-****

EXPERIENCE

present Merrill Lynch, Scottsdale, Arizona

Global Wealth Management

o Trade a master portfolio of life sciences companies based on my

own proprietary and fundamental research.

o Active member of the AZ Bio industry organization and frequent

presenter and panel member on the topics of life sciences

funding and corporate partnering strategies.

o Building a broad base of high-net-worth clients nationally, with

a particular focus on active corporate executives, doctors and

life sciences professionals.

o Hold NASD Series 7, 66 and 31 registrations; AZ variable

life/health insurance licensed.

8/05 - 8/06 Susquehanna International Group [SIG], New York, New York

Director, Healthcare Investment Banking

o Recruited as the designated lead banker with calling and

execution responsibility for all life sciences companies.

o Substantial life sciences industry knowledge; established

dialogue and relationships with numerous public and private

companies in the sector.

o Extensive transaction experience, including Public Offerings,

Mergers & Acquisitions, Private Placements and Strategic

Financial Advisory assignments.

9/03 - 4/05 First Albany Capital (now Broadpoint.Gleacher), New York, New

York

Vice President, Healthcare Investment Banking

o Designated lead banker with calling and execution responsibility

for biotechnology and specialty pharmaceutical companies.

o Responsible for evaluating, initiating and maintaining several

of the firm's relationships with venture capital, private equity

and crossover firms active in the life sciences.

4/00 - 6/03 RBC Capital Markets / Tucker Anthony Sutro, New York, New York

Vice President, Healthcare Investment Banking

o Operated as an Associate and later Vice President in the

Healthcare Investment Banking Group and focused on public and

private equity financings, mergers & acquisitions and corporate

advisory services.

o Served as a member of the PIPE placement group, assisting in the

origination, structuring and distribution of PIPE offerings

across all industry verticals.

7/98 - 4/00 Deloitte Consulting, New York, New York

Senior Consultant, Healthcare Competitive Strategies

o Developed comprehensive financial and strategic solutions for

global healthcare organizations.

o Authored Dealing With The Cost-Quality-Revenue Squeeze in

Healthcare and co-authored Pharmaceutical Pathways to Victory:

Why M&A Isn't the Total Rx (TRx) ( Deloitte Research

publications.

5/97 - 12/97 Eli Lilly & Co., PCS Health Systems, Scottsdale, Arizona

Clinical Management Intern

o Developed therapeutic use guidelines for various therapeutic

drug classes, including NSAID's and anti-asthmatics.

o Monitored drugs in various phases of clinical development in

order to assess their potential impact on PCS formularies &

direct strategic partnering objectives.

EDUCATION

Arizona State University, Tempe, Arizona

Dual Degree Program:

Master of Business Administration, Regent's Scholar, 1998

Master of Health Services Administration, 1998

University of Kansas School of Medicine, Kansas City, Kansas

Completed core requirements to achieve Doctor of Medicine,

Genetics research fellow, 1992-1996

University of Kansas, Lawrence, Kansas

Bachelor of Arts, Biochemistry, University Honors Program,

Departmental Honors, Magna Cum Laude, 1992

Jack H. Suggs

e: abne60@r.postjobfree.com ( t: 917-***-****

TRANSACTION EXPERIENCE

Company

Transaction Size

Business description Transaction/Project

Description (in millions)

Completed Assignments

NeurogesX, Inc. Initial Public Offering

$ 44

Treatments for neuropathic pain

ActivBiotics, Inc. Initial Public Offering

WD

Pharmaceuticals to treat cardiovascular disease

Accentia Biopharmaceuticals, Inc. Private Investment in

Public Equity $ 10

Specialty pharmaceuticals for pulmonary disease & cancer

Eximias Pharmaceutical Corp. Acquisition by YM Biosciences

Inc. $ 40

Cancer biopharmaceuticals

Altus Pharmaceuticals Inc. Initial Public Offering

$ 105

Protein therapeutics for GI & metabolic disorders

IOMAI Corporation Initial Public Offering

$ 35

Transcutaneous vaccine products

Avalon Pharmaceuticals Initial Public Offering

$ 29

Drugs for the treatment of cancer & related disorders

Osteologix, Inc. Reverse Merger & Private

Investment in Public Equity $ 10

Pharmaceuticals for bone & cartilage disorders

Vical Inc. Private Investment in Public Equity

$ 23

Infectious disease vaccines & cancer immunotherapies

Gentium SpA Private Investment in Public Equity

$ 11

Biopharmaceuticals for vascular disease & cancer

Metabasis Therapeutics Inc. Private Investment in Public

Equity $ 41

Drugs for the treatment of metabolic disease & cancer

Spectrum Pharmaceuticals Inc. Registered Direct

Offering $ 42

Drugs for the treatment of cancer & related disorders

Geron Corporationm Follow-On Public Offering

$ 72

Cancer biopharmaceuticals & cell-based therapies

Valera Pharmaceuticals Initial Public Offering

$ 34

Urology and endocrine specialty pharmaceuticals

DexCom Initial Public Offering

$ 56

Technologies for diabetes care

Peninsula Pharmaceuticals, Inc. Initial Public Offering

WD

Anti-infective biopharmaceuticals

XOMA Ltd. Convertible Senior Notes

$ 60

Diverse biopharmaceuticals

Martek Biosciences Corp. Follow-On Public

Offering $ 86

Pharmaceuticals and nutritional supplements

Hythiam, Inc. Private Investment in Public

Equity $ 23

Alcohol and drug addiction services

New River Pharmaceuticals Inc. Initial Public Offering

$ 34

Novel biopharmaceuticals for the CNS

Orthovita, Inc. Financial Advisory

$ 25

Developer of synthetic bone substitute products

Jack H. Suggs

e: abne60@r.postjobfree.com ( t: 917-***-****

TRANSACTION EXPERIENCE

Company

Transaction Size

Business description Transaction/Project

Description (in millions)

Completed Assignments (con't)

Senomyx, Inc. Initial Public Offering

$ 36

Novel flavor and flavor-enhancer ingredients

CV Therapeutics Inc. Subordinated Convertible Notes

$ 150

Cardiovascular biopharmaceuticals

Bone Care International, Inc. Follow-On Public

Offering $ 120

Vitamin D hormone replacement therapies

IMPAX Laboratories, Inc. Convertible Notes

$ 82

Generic & branded specialty pharmaceuticals

Adolor Corporation Follow-On Public Offering

$ 119

Novel analgesics and related therapeutics

NeoPharm, Inc. Follow-On Public Offering

$ 79

Anticancer biopharmaceuticals & liposomal drug delivery

Introgen Therapeutics, Inc. Private Investment in Public

Equity $ 20

Gene therapy products for the treatment of cancer

CV Therapeutics Inc. Subordinated Convertible

Debentures $ 100

Cardiovascular biopharmaceuticals

Charles River Laboratories International, Inc. Senior Convertible

Debentures $ 175

Clinical research tools & services

TiVo Inc. Private Investment in Public Equity

$ 53

Subscription-based personal television service

InKine Pharmaceutical Company, Inc. Private Investment in

Public Equity $ 10

Diversified specialty pharmaceuticals

Orthovita, Inc. Private Investment in Public

Equity $ 11

Developer of synthetic bone substitute products

Collagenex Pharmaceuticals, Inc. Private Investment in

Public Equity $ 10

Dental & dermatological specialty pharmaceuticals

EP MedSystems, Inc. Private Investment in Public

Equity $ 10

Electrophysiology and cardiac catheters

Inverness Medical Technology, Inc. Follow-On Public

Offering $ 104

Diabetes monitoring systems

Genta Incorporated Private Investment in Public

Equity $ 43

Emerging anticancer biopharmaceuticals

Radiance Medical Systems, Inc. Follow-On Public

Offering $ 27

Cardiovascular devices and vascular radiation systems

Caliper Technologies Corp. Private Investment in Public

Equity $ 110

Lab-on-a-chip technologies

CardioDynamics International Corp. Private Investment in

Public Equity $ 19

Non-invasive cardiac hemodynamic monitoring devices

LifeCell Corporation Private Investment in Public

Equity $ 10

Tissue engineering and cell preservation products

AVAX Technologies, Inc. Acquisition of

Genopoietic S.A. $ 10

Autologous cancer vaccines

Jack H. Suggs

e: abne60@r.postjobfree.com ( t: 917-***-****

TRANSACTION EXPERIENCE

Company

Transaction Size

Business description Transaction/Project

Description (in millions)

Completed Assignments (con't)

DRAXIS Health, Inc. Financial Advisory

$ ND

Specialty pharmaceuticals

Keryx Biopharmaceuticals, Inc. Initial Public Offering

$ 46

Novel drug discovery

The Immune Response Corporation Follow-On Public Offering

$ 17

Immune-based biopharmaceutical therapies

Organogenesis Corporation Private Investment in Public

Equity $ 20

Tissue engineering & skin replacement products

Talk Technology, Inc. Acquisition by The Agfa Group

$ ND

Integrated clinical speech recognition workflow solutions

Global Pharmaceutical Corporation Merger with IMPAX Laboratories

Inc. $ 150

Generic and branded specialty pharmaceuticals

ND: Not Disclosed

WD: Withdrawn

Contact this candidate